Opus Genetics is trading 10% up now at $4.22 on speculative positioning ahead of expected three-month topline data from the OPGx-BEST1 Cohort 1 study during the second week of September 2026.
- Cohort 1 enrollment was previously reported complete, with the anticipated data timeline confirmed.
- Shares gained 5.80% to $3.83 on September 1, extending the pre-data rally.